Clinical Trial

HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to understand the safety and estimate the efficacy of anti-CD3 x anti-HER2 bispecific antibody (HER2Bi) armed fresh peripheral blood mononuclear cells (HER2 FPBMC) for patients with metastatic breast or prostate cancer. Participants receive 5 weekly doses of CD33 FPBMC by intravenous infusion followed by 4 infusions every other week.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-06-13
notable Primary completion pushed: 2029-06 -> 2029-10 2026-06-13
minor Completion pushed: 2032-06 -> 2032-10 2026-06-13
Trial Details
NCT Number NCT07441889
Lead Sponsor University of Virginia
Conditions Breast Cancer, Prostate Cancer
Enrollment 23 participants
Start Date 2026-06
Primary Completion 2029-10 (estimated)
Study Completion 2032-10 (estimated)
Updated on ClinicalTrials.gov 2026-06-12